A broad array of cell-based assays designed for use with a variety of live cell experiments and procedures. Ideal for molecular and cell biology research applications.
The GeneBLAzer™ Jurkat Control Kit contains constitutively expressing (CMV-bla) and wildtype Jurkat cells to provide positive and negative controls, respectively, for evaluating beta-lactamase activity (Figure 1).
The GeneBLAzer™ CHO-K1 Control Kit contains constitutively expressing (CMV-bla) CHO-K1 cells and wildtype CHO-K1 cells to provide positive and negative controls for evaluating beta-lactamase activity.
The CellSensor™ dhfr(E2F)-bla NIH 3T3 Cell Line contains a beta-lactamase reporter gene under control of the E2F/DP1 binding sequence from the DHFR gene promoter, stably integrated into NIH 3T3 cells.
The BacMam Histone H3K4me3 Cellular Assay is a high-throughput screening (HTS) compatible TR-FRET assay for the interrogation of trimethylation at lysine 4 on histone H3 in a cellular format.
The BacMam Histone H3K27me3 Cellular Assay is a high-throughput screening (HTS) compatible TR-FRET assay for the interrogation of trimethylation at lysine 27 on histone H3 in a cellular format.
The LanthaScreen™ LRRK2 [pSer935] Cellular Assay Kit combines the flexibility of the BacMam gene delivery system with the robustness and power of our LanthaScreen™ TR-FRET technology.
The LanthaScreen™ LRRK2 G2019S [pSer935] Cellular Assay Kit combines the flexibility of the BacMam gene delivery system with the robustness and power of our LanthaScreen™ TR-FRET technology.
The CellSensor™ NFAT-bla Jurkat cell line contains a beta-lactamase reporter gene under control of a Nuclear Factor of Activated T Cells (NFAT) response element stably integrated into Jurkat cells.
The CRE-bla Jurkat cell line contains a beta-lactamase reporter gene under control of a cAMP response element (CRE) stably integrated into Jurkat cells.
Wnt signaling via Beta-catenin plays a central role in development and homeostasis. This pathway is invariably disrupted in colorectal tumors and commonly affected by mutation in other cancers.